IL9: Interleukin-9
Multifunctional cytokine secreted mainly by T-helper 2 lymphocytes and also mast cells or NKT cells that plays important roles in the immune response against parasites.
- Drugs that act on it: 1
- Approved: 0
- In phases 1 to 3: 1
- Sponsors: 1
Who is on it, and how far along
Every drug ChEMBL records acting on IL9, by the furthest stage it has reached for any use, coloured by modality.
How to read this
Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
- Antibody 1
| Drug | Furthest stage | Sponsor | Modality | Action | Open trials |
|---|---|---|---|---|---|
| Enokizumab | Phase 2 | MedImmune LLC | Antibody | InhibitorInterleukin-9 inhibitor | 0 |
- Neurodegenerative disease0.40
- Sjogren syndrome0.27
- Intestinal impaction0.20
- Asthma0.13
- Neoplasm0.12
- Rheumatoid arthritis0.11
- Infection0.11
- Systemic lupus erythematosus0.11
- Allergic rhinitis0.11
- B-cell chronic lymphocytic leukemia0.10
- Experimental autoimmune encephalomyelitis0.10
- Ulcerative colitis0.10
Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL3712932, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. Gene name, function (UniProt P15248, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets